Merck shares rise over 5% as drugmaker raises sales outlook
Merck & Co (MRK) shares rose 5.17% after reporting Q3 revenue of $18.1B, beating estimates, and raising its full-year sales outlook to $66.8B-$67.3B. Keytruda sales grew 6% to $8.6B, Winrevair up 93% to $694M, and animal health revenue up 4% to $1.7B. However, net income fell 12% to $5.07B due to higher operating expenses. Adjusted EPS declined 3% to $2.49. Merck also raised its adjusted earnings guidance to $2.77-$2.82 per share.
How this was made
The 30-second read
Why it matters
The earnings beat and outlook lift suggest near‑term upside, but margin pressure from higher expenses may limit long‑term gains.
Market read
Merck's earnings and guidance update are a primary catalyst for its stock and have sector‑wide implications.
What to watch
Potential headwinds from generic competition on Januvia/Janumet and Lagevrio declines.
Background
Merck's Q3 earnings beat and guidance raise come amid mixed product performance, with strong Keytruda sales offset by declines in older drugs.
Ticker impact
Merck reported Q3 revenue beat and raised full-year sales outlook, driving a 5.17% share rise.
upward pressure as market prices in the higher sales and earnings outlook
Guidance lift and beat on revenue are fresh, material information; the stock already moved >5% on the news.
Market effects
Boosts broader pharma sector sentiment, especially peers with oncology pipelines.
Positive for US large‑cap healthcare stocks.
Reinforces confidence in US biotech/ pharma earnings season.
Counterpoint
Higher R&D and restructuring costs could pressure margins if sales growth slows.
Key entities
- companyMerck & Co Inc
US pharmaceutical giant reporting Q3 results.
